

1.825. In accordance with 37 C.F.R. § 1.821(e), a copy of the above-submitted substitute SEQUENCE LISTING in ASCII computer readable form is also submitted on even date herewith to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington VA 22202. The contents of the paper version of the substitute SEQUENCE LISTING submitted herewith, and the computer readable form being submitted to Box Sequence, are the same and do not include new matter.

The amendments to the specification adding sequence identifiers are made to conform the above-referenced application to the requirements of 37 C.F.R. §§ 1.821 - 1.825.

Claims 48-91 have been added. The specification as originally filed fully supports the subject matter of claims 48-91. The subject matter of claim 48 is supported by original claim 1 and by the specification, for example, at Page 9, Lines 7-19 and by Figures 5A-C and 8. The subject matter of claim 49 is supported by original claim 2 and by the Examples. The subject matter of claim 50 is supported by original claim 8. The subject matter of claim 51 is supported by originally filed claim 3. The subject matter of claim 52 is supported by originally filed claim 4. The subject matter of claim 53 is supported by originally filed claim 5. The subject matter of claim 54 is supported by originally filed claim 6. The subject matter of claim 55 is supported by the specification at Page 11, Line 26 to Page 12, Line 8 and Example 5. The subject matter of claim 56 is supported by originally filed claim 7. The subject matter of claim 57 is supported by Figure 8. The subject matter of claim 58 is supported by Figure 4A and Figure 7A. The subject matter of claim 59 is supported by original claim 10. The subject matter of claim 60 is supported by original claim 11. The subject matter of claim 61 is supported by the specification at Page 11, Line 26 to Page 12, Line 8 and Example 5. The subject matter of claim 62 is supported by original claim 14 and by the specification, for example, at Page 9, Lines 7-19 and by Figures 5A-C and 8. The subject matter of claim 63 is supported by original claim 2 and by the Examples. The subject matter of claim 64 is supported by original claim 18. The subject matter of claim 65 is supported by original claim 22. The subject matter of claim 66 is supported by original claim 23. The subject matter of claim 67 is supported by original claim 5. The subject matter of claim 68 is supported by original claim 21. The subject matter of claim 69 is supported by the specification at Page 11, Line 26 to Page 12, Line 8 and Example 5. The subject matter of claim 70 is supported by original claim 20. The subject matter of claim 71 is supported by Figure 8.

The subject matter of claim 72 is supported by Figure 4A and Figure 7A. The subject matter of claim 73 is supported by original claim 20. The subject matter of claim 74 is supported by original claim 21. The subject matter of claim 75 is supported by original claim 24. The subject matter of claim 76 is supported by original claims 25 and 29. The subject matter of claim 77 is supported by original claim 29. The subject matter of claim 78 is supported by original claim 27. The subject matter of claim 79 is supported by original claim 28. The subject matter of claim 80 is supported by original claim 29. The subject matter of claim 81 is supported by original claim 30. The subject matter of claim 82 is supported by original claim 31. The subject matter of claim 83 is supported by original claim 37. The subject matter of claim 84 is supported by original claim 38. The subject matter of claim 85 is supported by original claim 32 and the Examples. The subject matter of claim 86 is supported by original claim 33. The subject matter of claim 87 is supported by original claim 34. The subject matter of claim 88 is supported by original claim 40. The subject matter of claim 89 is supported by original claim 42. The subject matter of claim 90 is supported by original claim 45. The subject matter of claim 91 is supported by original claim 47.

No new subject matter has been added to the specification or claims. The amendments have been made to clarify the specification and claims, and not for reasons of patentability. Therefore, the amendments are not intended to limit the scope of equivalents to which any claim element may be entitled.

PRELIMINARY AMENDMENT

Serial Number: 09/877,606

Filing Date: June 8, 2001

Title: ANTIGEN FOR DEVELOPING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS

COPY

Page 13

Dkt: 1676.0021US1

The Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to examination and consideration of the above-identified application.

Conclusion

The Examiner is invited to contact Applicants' Representative if there are any questions regarding this Response or if prosecution of this Application may be assisted thereby.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

MIN LU ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6961

Date

Oct. 17, 2002

By

Robin A. Chadwick

Robin A. Chadwick

Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being transmitted via facsimile to: Commissioner of Patents, Washington, D.C. 20231, on this 17th day of October, 2002.

Anne M. Richards

Name

Anne M. Richards
Signature